Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 326 participants.
Also called NCT02630316
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 326 participants
- Sponsor
- Registry
-
NCT02630316
-
- Other papers using this trial's data
- Inhaled Treprostinil Dosage in Pulmonary Hypertension Associated With Interstitial Lung Disease and Its Effects on Clinical Outcomes
- Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease
- Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Puerto Rico
- Registry status
- Completed
Technical summary
Registry record NCT02630316. Randomized; quadruple masking; primary purpose treatment. Start 2017-02-03 (actual); primary completion 2019-12-26 (actual). Results posted on 2021-07-13.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE
- Condition
- Pulmonary Hypertension
- Condition
- Interstitial Lung Disease
- Condition
- Combined Pulmonary Fibrosis and Emphysema
- Intervention (Drug)
- Inhaled Treprostinil
- Intervention (Drug)
- Placebo
- Lead sponsor
- United Therapeutics
Record details
- Record id
cardio:ct-nct02630316- Content hash
cf29aef1ec69f438ef71a27735f4efedbfa5fd53c90740cd86a7a0e5f789547c